SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-100553
Filing Date
2022-09-16
Accepted
2022-09-16 06:02:24
Documents
15
Period of Report
2022-09-15
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2225600d1_8k.htm   iXBRL 8-K 31844
2 EXHIBIT 3.1 tm2225600d1_ex3-1.htm EX-3.1 578587
7 GRAPHIC tm2225600d1_8kimg005.jpg GRAPHIC 199626
  Complete submission text file 0001104659-22-100553.txt   1202440

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nbrv-20220915.xsd EX-101.SCH 3268
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nbrv-20220915_def.xml EX-101.DEF 26444
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbrv-20220915_lab.xml EX-101.LAB 36200
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nbrv-20220915_pre.xml EX-101.PRE 25102
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2225600d1_8k_htm.xml XML 4974
Mailing Address 414 COMMERCE DRIVE STE 120 FORT WASHINGTON PA 19034
Business Address 25-28 NORTH WALL QUAY DUBLIN L2 D01 H104 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 221246904
SIC: 2834 Pharmaceutical Preparations